Travere Therapeutics (TVTX) reported Q4 EPS of ($0.76), $0.31 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $52.3 million versus the consensus estimate of $56.99 million.
Travere Therapeutics (TVTX) reported Q4 EPS of ($0.76), $0.31 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $52.3 million versus the consensus estimate of $56.99 million.